Related Articles by Review for PMID: 34424635

Year	Number of Results
2020	1
2021	6
2022	14
2023	10
2024	5
2025	1

1

Padda IS, Parmar M. Padda IS, et al. 2024 Feb 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Feb 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34424635 Free Books & Documents.

2

Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.

Vaz M, Silva V, Monteiro C, Silvestre S. Vaz M, et al. Clin Interv Aging. 2022 May 18;17:797-810. doi: 10.2147/CIA.S325026. eCollection 2022. Clin Interv Aging. 2022. PMID: 35611326 Free PMC article. Review.

3

Can we learn lessons from the FDA's approval of aducanumab?

Liu KY, Howard R. Liu KY, et al. Nat Rev Neurol. 2021 Nov;17(11):715-722. doi: 10.1038/s41582-021-00557-x. Epub 2021 Sep 17. Nat Rev Neurol. 2021. PMID: 34535787 Review.

4

A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.

Mukhopadhyay S, Banerjee D. Mukhopadhyay S, et al. J Alzheimers Dis. 2021;83(4):1537-1552. doi: 10.3233/JAD-215065. J Alzheimers Dis. 2021. PMID: 34366359 Review.

5

Aducanumab for the treatment of Alzheimer's disease: a systematic review.

Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS, Haque SN, Al Masud A, Saif-Ur-Rahman KM. Rahman A, et al. Psychogeriatrics. 2023 May;23(3):512-522. doi: 10.1111/psyg.12944. Epub 2023 Feb 12. Psychogeriatrics. 2023. PMID: 36775284 Free PMC article. Review.

6

"Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.

Behl T, Kaur I, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Alhazmi HA, Felemban SG, Alsubayiel AM, Bhatia S, Bungau S. Behl T, et al. Biomed Pharmacother. 2022 Apr;148:112746. doi: 10.1016/j.biopha.2022.112746. Epub 2022 Feb 26. Biomed Pharmacother. 2022. PMID: 35231697 Free article. Review.

7

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.

Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Tolar M, et al. Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w. Alzheimers Res Ther. 2020. PMID: 32787971 Free PMC article. Review.

8

Aducanumab for the treatment of Alzheimer's disease.

Tagliapietra M. Tagliapietra M. Drugs Today (Barc). 2022 Oct;58(10):465-477. doi: 10.1358/dot.2022.58.10.3422314. Drugs Today (Barc). 2022. PMID: 36305541 Review.

9

[Causal treatment of Alzheimer's disease: amyloid antibodies].

Pawlowski M, Warnecke T. Pawlowski M, et al. Inn Med (Heidelb). 2022 Sep;63(9):1000-1008. doi: 10.1007/s00108-022-01291-2. Epub 2022 Mar 15. Inn Med (Heidelb). 2022. PMID: 35290498 Review. German.

10

Aducanumab: First Approval.

Dhillon S. Dhillon S. Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z. Drugs. 2021. PMID: 34324167 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 34424635

35 results

Results by year